Mahendra Babu, J (2016) Formulation Development and Invitro Evalution of Gastroretentive Venlafaxine Hydrochloride Floating Tablets. Masters thesis, J. K. K. Nattraja College of Pharmacy, Komarapalayam.
|
Text
260103216mahendrababu.pdf Download (3MB) | Preview |
Abstract
INTRODUCTION: The design of an oral controlled drug delivery system (DDS) should be primarily aimed at achieving more predictable and increased bioavailability of drugs. However, the development process is precluded by several physiological difficulties, such as an inability to restrain and localize the DDS within desired regions of the gastrointestinal (GI) tract and the highly variable nature of gastric emptying process. It can be anticipated that, depending upon the physiological state of the subject and the design of pharmaceutical formulation, the emptying process can last from a few minutes to 12 hours (hr). This variability in turn may lead to unpredictable bioavailability and times to achieve peak plasma levels, since the majority of drugs are preferentially absorbed in the upper part of the small intestine. Furthermore, the relatively brief gastric emptying time (GET) in humans, which normally averages 2–3 hr through the major absorption zone (stomach or upper part of the intestine), can result in incomplete drug release from the DDS leading to diminished efficacy of the administered dose. Thus, control of placement of a DDS in a specific region of the GI tract offers numerous advantages, especially for drugs exhibiting an absorption window in the GI tract or drugs with a stability problem. Overall, the intimate contact of the DDS with the absorbing membrane has the potential to maximize drug absorption and may also influence the rate of drug absorption. These considerations have led to the development of oral controlled-release (CR) dosage forms possessing gastric retention capabilities. AIM OF STUDY: 1. The aim of this present work is to formulate a gastro retentive floating tablet of Venlafaxine HCl by direct compression method using various polymers such as Carbopol 934, Xanthan gum, and HPMC K-100M. 2. Venlafaxine HCl exhibits pH dependent solubility. It is more soluble in acidic pH and slightly soluble at neutral or alkaline condition (intestinal environment). Hence an attempt will be made to develop gastroretentive delivery system of Venlafaxine HCl which would increase the bioavailability of Venlafaxine HCl and also to reduce frequency of administration, thereby improving patient compliance and therapeutic efficacy. OBJECTIVE OF STUDY: a)Formulation and evaluation of sustained release tablet. b) To study the effect of mixture of drug, hydrophilic and hydrophobic cellulose polymers on release rate of sustained release tablet. c) To reduce the frequency of administration and to improve patient compliance by once daily sustained release formulation. d) To determine the chemical compatibility of formulation containing various ratio of polymer and drug. CONCLUSION: Floating Drug Delivery System are retained in the stomach for a longer time and assist in improving the oral controlled delivery of drugs that have an absorption window in the particular region of the GI tract as well as for controlling the release of the drug having site-specific absorption limitation. Venlafaxine HCl is a highly effective antidepressant was used as a model drug to develop a controlled release formulation. Venlafaxine HCl exhibits pH dependent solubility. It is more soluble in acidic pH and slightly soluble at neutral or alkaline condition (intestinal environment). Hence an attempt was made to develop gastroretentive delivery system of Venlafaxine HCl which increased the bioavailability of Venlafaxine HCl and also to reduce frequency of administration, thereby improving patient compliance and therapeutic efficacy.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | REG.No.261410270 |
| Uncontrolled Keywords: | Formulation Development ; Invitro Evalution ; Gastroretentive Venlafaxine ; Hydrochloride Floating Tablets |
| Subjects: | PHARMACY > Pharmaceutics |
| Depositing User: | Ravindran C |
| Date Deposited: | 23 Mar 2018 09:23 |
| Last Modified: | 23 Mar 2018 09:23 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/6483 |
Actions (login required)
 |
View Item |
